SecBot SecBot
PRESS-RELEASE ·Filed Mar 6, 2026

DAWN

Day One Biopharmaceuticals, Inc.
BULLISH
Impact 9/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Traders should consider positioning for near-term upside as the stock is likely to trade close to the $21.50 offer price once the tender offer commences. Arbitrage opportunities may exist if shares trade below the offer price, though risks include deal delays or failure to secure antitrust approval.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$21.20
T+0 close · Mar 6, 2026 · via day close
Latest settled
+1.23%
T+20 · $21.46
Vs SPY
+3.27%
α at T+20
Next horizon
T+60
due 6mo ago
  1. T+0 · Mar 6 $21.20entry
  2. T+1 · 8mo ago +0.61%α −0.23% · $21.33
  3. T+5 · 8mo ago +0.52%α +2.05% · $21.31
  4. T+20 · 8mo ago +1.23%α +3.27% · $21.46
  5. T+60 · due 6mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Servier has agreed to acquire Day One Biopharmaceuticals (DAWN) for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The offer includes a 68% premium over Day One's closing price on March 5, 2026, and is expected to close in Q2 2026, pending regulatory approval and shareholder tender.

Key Financial Metrics

Deal Value
$2.5B

Key Facts

  • Servier is acquiring Day One Biopharmaceuticals for $21.50 per share in cash
  • Total equity value of the transaction is approximately $2.5 billion
  • Offer represents a 68% premium over DAWN's March 5, 2026 closing price and 86% over one-month VWAP
  • Transaction expected to close in Q2 2026, subject to antitrust clearance and shareholder tender
  • Day One's Board recommends shareholders tender their shares

Financial Impact

$2.5 billion total equity value, $21.50 per share cash consideration

dilutionenterprise valueshare price

Risk Factors

  • Deal is contingent on U.S. antitrust clearance, which could delay or block the transaction
  • Completion requires tender of a majority of outstanding shares, exposing the deal to shareholder holdouts
  • Potential for competing bids or litigation could alter or terminate the agreement

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3251033

Track record

6 reports on DAWN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 4, 202628w ago 15-12G Neutral 5/10 No price data
  2. Apr 23, 202629w ago 25-NSE Neutral 9/10 Entry $21.53 No price data
  3. Apr 23, 202629w ago 8-K Neutral 9/10 Entry $21.53 No price data
  4. Apr 17, 202630w ago 10-K/A Neutral 4/10 Entry $21.48 No price data
  5. Mar 6, 202636w ago Press Release Bullish 9/10 Viewing Entry $21.20 to $21.46 ▲ +1.23% +3.27% vs SPY
  6. Feb 24, 202637w ago 8-K Bullish 8/10 Entry $10.92 to $21.37 ▲ +95.79% +101.02% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 6, 2026